Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

The biologic treatment landscape for severe 

 and chronic obstructive pulmonary disease (COPD) continues to expand, with 7 approved biologics now available for asthma and 2 for eosinophilic COPD, yet real-world integration has remained uneven across practice settings and patient populations. Short-acting beta-agonist (SABA) overuse — defined as ≥3 canisters per year — is now recognized as a marker of inadequate disease control and is independently associated with increased exacerbation risk and all-cause mortality, yet it remains systematically undercaptured in clinical practice.¹ 

Oral corticosteroid (OCS) burden represents a parallel and equally undermonitored problem: large cohort analyses have demonstrated dose-response relationships between cumulative OCS exposure and serious adverse outcomes — including type 2 diabetes, osteoporosis, and cardiovascular events — beginning at cumulative prednisolone-equivalent doses as low as 500 mg, a threshold easily reached within 1 to 2 acute exacerbation courses per year.² 

Recently, the LIBERTY ASTHMA VENTURE trial established that dupilumab enables meaningful and durable OCS reduction in steroid-dependent severe asthma, with approximately 80% of treated patients achieving clinically significant OCS tapering — including concurrent FEV1 improvement of approximately 220 mL despite reduced corticosteroid exposure.³ In COPD, dupilumab and mepolizumab are now endorsed by GOLD 2026 as add-on options for patients with eosinophilic disease and ongoing exacerbations despite triple inhaled therapy, based on the BOREAS, NOTUS, and MATINEE trial programs.⁴˒⁵˒⁶

 convened a virtual clinical forum in May 2026 moderated by Jacqueline B. Sutter, DO, a pulmonologist and critical care physician in the greater Philadelphia area that included pulmonologists from a variety of backgrounds of care. This practice-setting heterogeneity distinguished the discussion from predominantly specialist-to-specialist forums and grounded the conversation in the referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

The forum convened as the NIMBLE trial — confirming non-inferiority of switching from mepolizumab or benralizumab to depemokimab — had recently been published, and as CT-based mucus plug scoring data from the VESTIGE and CASCADE trials were generating active discussion about whether imaging biomarkers might eventually supplement eosinophils and FeNO in guiding biologic selection in asthma.⁷˒⁸˒⁹ Both conversations came up directly in the forum's discussion, as did renewed attention to the SABINA program's data on SABA overuse as a more reliable, real-time marker of disease burden than patient self-report.¹ In COPD, GOLD 2026's formal endorsement of biologic escalation — alongside a strengthened recommendation for baseline CT in all patients — represented a framework the group applied cautiously, acknowledging that the patient selection algorithm that practitioners need most is still in development.

The asthma portion of the forum was shaped by the heterogeneity of the panel. A family physician described a referral threshold after step-up ICS and LTRA failure, familiarity with dupilumab and omalizumab by brand name, and reliance on specialists for final agent selection — a common pattern in primary care that the moderator acknowledged as appropriate but also noted creates significant workflow burden on pulmonology and allergy practices that absorb these referrals. Panelists described checking blood eosinophils, IgE, and allergen panels on most new asthma patients and using FeNO both for initial phenotyping and longitudinal monitoring; practice access to FeNO varied, with NIH and academic clinic sites using it routinely and community practices less consistently. OCS tracking emerged as a particular focus: panelists described the practical challenge of calculating cumulative exposure across fragmented care systems and proposed EMR-based cumulative OCS calculators as a high-priority workflow improvement. The VENTURE trial's OCS-sparing and FEV1 improvement data was highlighted by Sutter as among the most clinically compelling arguments for dupilumab in steroid-dependent patients who may not have reliable eosinophil counts. Depemokimab's twice-yearly dosing drew split opinion — viewed as appealing by adherence-challenged or travel-limited patients, and with some caution by Sutter regarding the challenge of recognizing suboptimal control across a 6-month interval. The mucus plug data from VESTIGE and CASCADE was broadly acknowledged as mechanistically explanatory but not yet practice-changing, with one panelist noting that IL-13's role in mucus hypersecretion is well established and the imaging data reinforces rather than redefines that understanding.

“As a fairly young graduate who kind of was trained in the era of biologics. I would say I probably became more, I don't want to say aggressive, but I definitely became more mindful of maybe considering earlier transitions to biologics,” a panelist said.

The COPD discussion centered on the persistent challenge of patient selection and the slower pace of biologic adoption relative to asthma. Panelists described the inpatient exacerbation as the most reliable clinical trigger for eosinophil measurement in COPD, acknowledging that by that point patients have typically already received systemic steroids, suppressing the count. A substantive conceptual discussion about whether "eosinophilic COPD" represents a distinct phenotype or simply ACOS relabeled — prompted by the most experienced panelist, with 32 years in practice — reflected a real divide in clinical thinking that the moderator framed pragmatically: if T2 inflammation is present, treat it regardless of diagnostic label. Polling results from the COPD segment were consistent with every prior forum in this HCPLive series: payer support and reimbursement guidance, followed by clearer patient selection algorithms, were the factors practitioners most needed. Panelists closed with cautious optimism noting that a generation trained in the era of biologics is now entering independent practice with more structured prescribing frameworks for asthma than for COPD, and expressing that the COPD side of this field is most in need of the kind of phenotypic clarity that eos and FeNO eventually provided in asthma.

Larsson K, Stallberg B, Lisspers K, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. 

 2020;55(4):1901872. doi:10.1183/13993003.01872-2019

Loftus PA, Wise SK. Cumulative oral corticosteroid exposure in asthma and morbidity: a dose-response relationship. 

 [Danish cohort reference]: Ekberg-Aronsson M et al. Confirmed reference: Søndergaard MB, Hilberg O, Davidsen JR, et al. Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality. 

 2022;60(2):2102229. doi:10.1183/13993003.02229-2021.

Articles

A clinical forum discussed referral dynamics, access barriers, and patient health literacy challenges that shape biologic use in the real world.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Beyond Step-Up Therapy: Biologic Initiation, Selection, and Access in Asthma and COPD

Jonathan A. Bernstein, MD: University of Cincinnati

Sequencing Emerging Therapies in CSU, With Jonathan Bernstein, MD

Jonathan Bernstein, MD, professor of medicine at the University of Cincinnati and physician with Bernstein Allergy Group and the Bernstein Clinical Research Center, outlined how clinicians may approach treatment sequencing in

 as newer targeted therapies expand options beyond antihistamines and omalizumab. Speaking with 

 in Palm Beach, Florida, Bernstein emphasized that treatment selection should remain individualized despite forthcoming guideline recommendations.

“If they [have] never been treated, then we're going to start using high-dose antihistamines to make sure they truly are not ineffective,” he said.

He added that this first trial of second-generation antihistamines should include dose escalation up to 4 times the standard recommended dose. He noted that some patients may not have used antihistamines consistently or appropriately before referral, making confirmation of treatment failure an important first step.

Bernstein indicated that updated CSU guidelines are expected to continue recommending omalizumab as the preferred next-line therapy based on the strength and certainty of available evidence, as well as its established safety profile. Although omalizumab carries a boxed warning for anaphylaxis, he noted that concerns largely stem from reports in asthma populations rather than patients with urticaria.

However, Bernstein emphasized that guideline recommendations may not be appropriate for every patient. Individuals with very low immunoglobulin E (IgE) levels and evidence of autoimmune disease may represent a distinct phenotype that could warrant consideration of alternative therapies, including dupilumab or remibrutinib.

He noted that biomarkers are not expected to be incorporated into formal treatment algorithms because evidence supporting biomarker-guided decision-making remains limited. Nevertheless, Bernstein encouraged clinicians to recognize differences among patients and consider how biomarkers may eventually help identify treatment-responsive subgroups.

Cyclosporine remains an option for patients with difficult-to-treat disease, particularly those with chronic autoimmune urticaria, according to Bernstein. However, he noted its use requires monitoring for adverse effects, including hypertension and renal toxicity, and it is expected to occupy a later position in treatment algorithms as biologic and targeted therapies become more widely available.

Bernstein also highlighted the importance of obtaining biomarker assessments before initiating omalizumab when testing is planned. He explained that measurements such as total IgE, thyroid peroxidase antibodies, the CU Index, and basophil activation testing can potentially help characterize disease subtypes, but results may be affected once omalizumab therapy begins.

As treatment options continue to expand, Bernstein said additional real-world evidence and controlled studies will be needed to clarify how biomarkers and patient phenotypes can inform therapeutic sequencing in CSU.

Bernstein J. CSU biomarkers and advanced treatments. Poster presented at EAC 2026 on May 29.

Videos

 Bernstein discussed treatment sequencing, biomarker use, and evolving chronic spontaneous urticaria management strategies during an interview at EAC 2026.


Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Dr. Kiera Booth, MD, is a board-certified dermatologist practicing at Premier Dermatology & Cosmetic Surgery in the Newark and Middletown, Deleware areas.

Discussing Raising HS Awareness and Treatments, With Kiera Booth, MD

Hidradenitis Suppurativa (HS) Awareness Week

 highlights the burden of the chronic inflammatory skin disease, Kiera Booth, MD, a board-certified dermatologist with Premier Dermatology and Cosmetic Surgery in Delaware, highlighted clinicians’ greater number of tools than ever to improve outcomes for individuals living with moderate-to-severe HS.

, Booth noted treatment selection begins with understanding a patient's goals and disease burden. While some individuals experience severe but infrequent flares, others contend with frequent lesions that significantly impact quality of life. Tailoring treatment to these experiences remains a critical part of care.

Booth highlighted the evolution of the HS treatment landscape in recent years, particularly with the arrival of newer biologic agents. These additions have expanded therapeutic options and enabled dermatologists to help more patients attain meaningful levels of disease control. Looking ahead, she anticipates even greater progress as multiple investigational therapies continue through clinical development.

Beyond pharmacologic treatment, Booth highlighted the growing role of procedural interventions such as deroofing. She described the technique as highly impactful for patients with chronic tunnels and recurrent lesions, particularly those who have experienced delays in diagnosis. Compared with some older surgical approaches, deroofing may reduce the likelihood of recurrence while addressing areas of persistent disease.

Delayed diagnosis remains one of the most significant challenges in HS care, according to Booth. Many patients initially seek treatment in emergency departments, where acute flares may be addressed without establishing long-term disease management. Delays can also occur when patients hesitate to begin systemic therapies. Booth stressed the importance of controlling inflammation early, noting that prolonged disease activity can lead to permanent scarring, tunnels, and other structural skin changes.

Although therapeutic options continue to expand, Booth acknowledged that unmet needs remain. Not every patient responds adequately to currently available treatments, and comorbidities such as Crohn’s disease or ulcerative colitis can limit the use of certain therapies.

Among emerging treatments, Booth identified Janus kinase (JAK) inhibitors as one of the most promising developments. She said oral JAK therapies could offer potent anti-inflammatory effects while potentially benefiting patients with multiple inflammatory conditions. Booth also encouraged clinicians to familiarize themselves with evolving safety data surrounding JAK inhibitors so they can confidently discuss risks and benefits with patients.

For HS Awareness Week, Booth hopes clinicians feel empowered to engage with HS care. She emphasized that today's therapeutic landscape is dramatically different from a decade ago, with safe and effective options capable of producing meaningful improvements in patients' lives.

Booth had no disclosures of note to highlight.

Krueger JG, Frew J, Wolk K, et al. Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape. Br J Dermatol. 2024 Jan 23;190(2):149-162. 

Ribero S, Dapavo P, Casalegno C; HS Awareness Working Group. Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light. J Eur Acad Dermatol Venereol. 2019 Oct;33 Suppl 6:7-9. 

This interview highlights key facts regarding HS in honor of Hidradenitis Suppurativa (HS) Awareness Week, featuring Kiera Booth, MD.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Image Credit: US Food and Drug Administration

 has accepted a supplemental new drug application (sNDA) for mavacamten (Camzyos) for adolescents with symptomatic 

obstructive hypertrophic cardiomyopathy (oHCM)

Announced by parent company Bristol Myers Squibb on June 1, 2026, the FDA has granted the sNDA Priority Review for patients aged 12 to <18. The FDA has also assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 30, 2026. If approved, the application would expand the currently approved US indication for mavacamten beyond adults with symptomatic New York Heart Association class II-III oHCM.

“The acceptance of this NDA allows us the potential to extend our leadership in oHCM to a younger patient population with a high unmet medical need,” Cristian Massacesi, MD, executive vice president, chief medical officer, and head of development at Bristol Myers Squibb, said in a statement. “We are encouraged by the possibility of bringing this potentially paradigm-shifting treatment to adolescents at a time when a condition like oHCM can significantly impact both physical and emotional aspects of their lives.”

FDA priority review; PDUFA September 30, 2026

Mavacamten is a selective, reversible, allosteric inhibitor of cardiac myosin. In oHCM, the agent is intended to reduce excessive actin-myosin cross-bridge formation and myocardial contractility, with downstream effects on left ventricular outflow tract (LVOT) obstruction. The drug carries a boxed warning for risk of 

 due to systolic dysfunction and is available in the United States only through the Camzyos Risk Evaluation and Mitigation Strategy program.

The current US label is limited to adults with symptomatic NYHA class II-III oHCM to improve functional capacity and symptoms. In the announcement, Bristol Myers Squibb reported that mavacamten has been prescribed by >4500 clinicians to nearly 25,000 patients in the United States.

The sNDA is supported by SCOUT-HCM, a phase 3, randomized, double-blind, placebo-controlled, international trial enrolling 44 adolescents aged 12 to >18 years with symptomatic oHCM. The trial included 3 treatment periods totaling up to 200 weeks: a 28-week placebo-controlled period, a 28-week active-treatment period in which participants initially assigned to placebo cross over to mavacamten, and an open-label long-term extension for ≤144 weeks.

The primary endpoint was change from baseline to week 28 in Valsalva LVOT gradient. Secondary endpoints included resting and postexercise LVOT gradients, peak oxygen consumption, symptom and health status measures, and safety. SCOUT-HCM met its primary endpoint, with a clinically meaningful and statistically significant reduction from baseline in Valsalva LVOT gradient at week 28 for mavacamten compared with placebo.

Bristol Myers Squibb stated that the safety profile in adolescents was similar to that in adults and that no participant had a left ventricular ejection fraction below 50% over the 28-week period. In adult labeling, reductions in LVEF below 50% occurred in 6% of patients receiving mavacamten and 2% receiving placebo in EXPLORER-HCM; dizziness and syncope were adverse reactions reported more often with mavacamten than placebo.

Safety Considerations and Regulatory Next Steps

The proposed adolescent indication would enter a therapeutic area with limited pediatric-specific pharmacologic evidence. Hypertrophic cardiomyopathy (HCM) can be associated with pathogenic or suspected pathogenic sarcomeric variants, and obstructive physiology may contribute to exertional symptoms. Contemporary guidelines emphasize individualized evaluation of symptoms, obstruction, arrhythmia risk, family history, and treatment goals in patients with HCM, including referral to centers with disease-specific expertise when appropriate.

For mavacamten, the key safety issue remains systolic dysfunction. The US prescribing information requires echocardiographic assessment of LVEF before and during treatment; initiation is not recommended in patients with LVEF <55%, and interruption is required if LVEF falls below 50% or if heart failure symptoms or worsening clinical status occur. The label also lists contraindications with strong CYP2C19 inhibitors and with moderate to strong CYP2C19 or moderate to strong CYP3A4 inducers because of potential effects on exposure and heart failure risk or reduced efficacy.

Bristol Myers Squibb. U.S. Food and Drug Administration accepts for Priority Review Bristol Myers Squibb’s supplemental New Drug Application for Camzyos (mavacamten) to treat adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). BusinessWire. Published June 1, 2026. Accessed June 1, 2026. 

https://www.businesswire.com/news/home/20260529154810/en/U.S.-Food-and-Drug-Administration-Accepts-for-Priority-Review-Bristol-Myers-Squibbs-Supplemental-New-Drug-Application-for-Camzyos-mavacamten-to-Treat-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM

Bristol Myers Squibb. Camzyos (mavacamten) prescribing information. April 2025. Accessed June 1, 2026. 

https://packageinserts.bms.com/pi/pi_camzyos.pdf

Bristol-Myers Squibb. A study to evaluate mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy. ClinicalTrials.gov Identifier: NCT06253221. Updated December 19, 2025. Accessed June 1, 2026. 

https://clinicaltrials.gov/study/NCT06253221

Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2020;76(25):3022-3055. 

FDA accepted a priority review sNDA for mavacamten in adolescents with symptomatic obstructive hypertrophic cardiomyopathy.

FDA News

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Cardiomyopathy

Mavacamten sNDA Gets FDA Priority Review for Adolescent Obstructive HCM

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

 has accepted the Biologics License Application (BLA) for accelerated approval of povetacicept in adults with 

, with an assigned Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026.

 announced the decision on June 1, 2026, supported by positive data from a prespecified week 36 interim analysis of the ongoing phase 3 RAINIER trial, in which povetacicept achieved a 52% reduction in urine protein-to-creatinine ratio (UPCR) from baseline.

Povetacicept is an investigational engineered fusion protein and dual inhibitor of the BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand) cytokines. Through its engineered TACI domain, povetacicept has demonstrated improved binding affinity, potency, pharmacokinetics, and tissue distribution compared with other APRIL, BAFF, and dual BAFF/APRIL inhibitors in preclinical studies.

The randomized, double-blind, placebo-controlled phase 3 RAINIER trial evaluated the efficacy of povetacicept in reducing proteinuria and preserving kidney function. The study enrolled 605 patients, who were randomized to receive 80 mg povetacicept administered subcutaneously every 4 weeks in addition to standard care or placebo.

The trial's primary endpoint was change in 24-hour UPCR at week 36. The 2 alpha-controlled secondary endpoints were change in serum galactose-deficient IgA1 (Gd-IgA1) and the proportion of patients achieving hematuria resolution at week 36. Exploratory endpoints included the proportion of patients achieving a 24-hour UPCR <0.5 g/g, a threshold consistent with recent Kidney Disease: Improving Global Outcomes (KDIGO) guidance.¹

For the first secondary endpoint, patients treated with povetacicept experienced a 77.4% reduction in Gd-IgA1 compared with a 9.1% increase in the placebo group, yielding a treatment difference of 79.3% versus placebo (P <.0001) from baseline.¹

For the second secondary endpoint, among patients with baseline hematuria, 85.1% of those receiving povetacicept achieved hematuria resolution compared with 23.4% of patients receiving placebo, yielding a treatment difference of 61.7% versus placebo (P <.0001).¹

Overall, povetacicept was generally safe and well tolerated, with most adverse events (AEs) characterized as mild to moderate.¹

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy | Vertex Pharmaceuticals Newsroom. Vertex Pharmaceuticals Newsroom. Published 2026. Accessed June 1, 2026. 

https://news.vrtx.com/news-releases/news-release-details/vertex-announces-us-fda-acceptance-biologics-license-application

Hillenbrand A. RAINIER: Povetacicept Reduces Proteinuria By 52.0%. HCPLive. Published March 9, 2026. Accessed June 1, 2026. 

https://www.hcplive.com/view/ranier-povetacicept-achieves-primary-and-all-secondary-endpoints-for-igan

FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.


IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

FDA Accepts BLA for Povetacicept in IgA Nephropathy

Jeanine Downie, MD, is a board-certified dermatologist, and founder of image Dermatology PC in Montclair, NJ.

This segment of the Skin of Color Savvy podcast highlights how dermatologists can improve sunscreen adherence among individuals with skin of color.

How Dermatologists Can Tailor Sunscreen Counseling for Skin of Color

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Hepatology

The HCPFive: Top News for Healthcare Providers from the Week of 05/24

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover topline data from the TRIUMPH-1 trial of retatrutide for obesity management.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight

Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria  at EAC 2026.

Endotyping & Biomarkers in CSU, With Jonathan Bernstein, MD

This interview highlights topline findings from Part B of the phase 2 APEX trial highlight the efficacy of zumilokibart (APG777) in adults with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Discussing Zumilokibart Data in Atopic Dermatitis, With Ruth Ann Vleugels, MD, MPH, MBA

Tatiana V. Kudryashova, PhD, from the University of Pittsburgh.

In this Q&A, Tatiana V. Kudryashova, PhD, discusses new data presented at ATS 2026 that show silencing E2F2 suppresses hyperproliferation in PAH smooth muscle cells.

Could E2F2 Offer a More Precise Anti-Remodeling Target in PAH?

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Pooled B-Well phase 3 data show bepirovirsen achieved a 19% functional cure rate in CHB vs 0% with standard of care alone.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Bepirovirsen Achieves 19% Functional Cure in Chronic Hepatitis B

The FDA has approved fast-acting inhaled insulin Afrezza for pediatric patients aged 6-18 years with T1D or T2D.

Type 1 Diabetes

Type 2 Diabetes

FDA Approves Inhaled Insulin Afrezza for Pediatric Patients With Diabetes

This episode covers the FDA’s recent approval of MannKind’s inhaled insulin Afrezza for patients aged 6-18 years with either T1D or T2D.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: FDA Approves Afrezza Inhaled Insulin for Pediatric Patients

Diabetes Dialogue cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the recent approval of the Libre Duo and Libre Duo 10 Day monitors.

Latest News

Beyond Step-Up Therapy: Biologic Initiation, Selection, and Access in Asthma and COPD

Sequencing Emerging Therapies in CSU, With Jonathan Bernstein, MD

Discussing Raising HS Awareness and Treatments, With Kiera Booth, MD

Mavacamten sNDA Gets FDA Priority Review for Adolescent Obstructive HCM

FDA Accepts BLA for Povetacicept in IgA Nephropathy